Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon (Nasdaq: PLRZ) has signed a non-binding Letter of Intent (LOI) with an unnamed biotech company focused on psychedelic-derived therapeutics to develop a novel intranasal formulation for psychedelic-based treatments. The collaboration will leverage Polyrizon's proprietary intranasal hydrogel platform to optimize drug delivery.
Under the LOI terms, Polyrizon will lead the formulation development using its mucoadhesive drug delivery technology, while the psychedelic company will fund research and development, including feasibility studies. Upon successful proof of concept, the parties plan to negotiate a definitive agreement covering IP ownership, commercialization rights, and financial terms, with Polyrizon receiving royalties on future product commercialization.
Polyrizon (Nasdaq: PLRZ) ha firmato una Lettera di Intenti (LOI) non vincolante con un'azienda biotech non nominata, focalizzata su terapie derivate da psichedelici, per sviluppare una nuova formulazione intranasale per trattamenti basati su psichedelici. La collaborazione sfrutterà la piattaforma proprietaria di idrogel intranasale di Polyrizon per ottimizzare la somministrazione del farmaco.
Secondo i termini della LOI, Polyrizon guiderà lo sviluppo della formulazione utilizzando la sua tecnologia di somministrazione mucoadesiva, mentre l'azienda psichedelica finanzierà la ricerca e lo sviluppo, inclusi studi di fattibilità. Una volta dimostrato con successo il concetto, le parti pianificheranno di negoziare un accordo definitivo che copra la proprietà intellettuale, i diritti di commercializzazione e i termini finanziari, con Polyrizon che riceverà royalties sulla futura commercializzazione del prodotto.
Polyrizon (Nasdaq: PLRZ) ha firmado una Carta de Intención (LOI) no vinculante con una compañía biotecnológica no revelada, centrada en terapias derivadas de psicodélicos, para desarrollar una nueva formulación intranasal para tratamientos basados en psicodélicos. La colaboración aprovechará la plataforma de hidrogel intranasal patentada de Polyrizon para optimizar la entrega de medicamentos.
Según los términos de la LOI, Polyrizon liderará el desarrollo de la formulación utilizando su tecnología de entrega de medicamentos mucoadhesiva, mientras que la compañía psicodélica financiará la investigación y el desarrollo, incluidos los estudios de viabilidad. Una vez que se demuestre con éxito el concepto, las partes planean negociar un acuerdo definitivo que cubra la propiedad intelectual, los derechos de comercialización y los términos financieros, con Polyrizon recibiendo regalías sobre la futura comercialización del producto.
Polyrizon (Nasdaq: PLRZ)는 사이키델릭 유래 치료제에 집중하는 익명의 생명공학 회사와 사이키델릭 기반 치료를 위한 새로운 비강 제형 개발을 위한 비구속적 의향서(LOI)를 체결했습니다. 이 협력은 약물 전달 최적화를 위해 Polyrizon의 독점 비강 하이드로겔 플랫폼을 활용할 것입니다.
LOI 조건에 따라 Polyrizon은 점착성 약물 전달 기술을 사용하여 제형 개발을 주도하고, 사이키델릭 회사는 연구 및 개발, 포함하여 타당성 연구를 자금 지원할 것입니다. 개념 증명이 성공적으로 이루어진 후, 양측은 지식 재산권 소유, 상업화 권리 및 재무 조건을 포함하는 최종 계약을 협상할 계획이며, Polyrizon은 향후 제품 상업화에 대한 로열티를 받을 것입니다.
Polyrizon (Nasdaq: PLRZ) a signé une Lettre d'Intention (LOI) non contraignante avec une entreprise biotechnologique non nommée, spécialisée dans les thérapies dérivées des psychédéliques, pour développer une nouvelle formulation intranasale pour les traitements basés sur les psychédéliques. La collaboration tirera parti de la plateforme d'hydrogel intranasal propriétaire de Polyrizon pour optimiser l'administration des médicaments.
Selon les termes de la LOI, Polyrizon dirigera le développement de la formulation en utilisant sa technologie de délivrance de médicaments muco-adhésifs, tandis que l'entreprise psychédélique financera la recherche et le développement, y compris les études de faisabilité. Une fois le concept prouvé avec succès, les parties prévoient de négocier un accord définitif couvrant la propriété intellectuelle, les droits de commercialisation et les conditions financières, Polyrizon recevant des redevances sur la commercialisation future du produit.
Polyrizon (Nasdaq: PLRZ) hat eine nicht verbindliche Absichtserklärung (LOI) mit einem nicht genannten Biotech-Unternehmen unterzeichnet, das sich auf psychedelisch abgeleitete Therapeutika konzentriert, um eine neuartige intranasale Formulierung für psychedelisch basierte Behandlungen zu entwickeln. Die Zusammenarbeit wird die proprietäre intranasale Hydrogel-Plattform von Polyrizon nutzen, um die Medikamentenverabreichung zu optimieren.
Gemäß den Bedingungen der LOI wird Polyrizon die Formulierungsentwicklung mit seiner mucoadhesiven Medikamentenverabreichungstechnologie leiten, während das psychedelische Unternehmen die Forschung und Entwicklung, einschließlich Machbarkeitsstudien, finanzieren wird. Nach erfolgreichem Nachweis des Konzepts planen die Parteien, eine endgültige Vereinbarung zu verhandeln, die das Eigentum an geistigem Eigentum, die Vermarktungsrechte und die finanziellen Bedingungen abdeckt, wobei Polyrizon Lizenzgebühren für die zukünftige Vermarktung des Produkts erhalten wird.
- Potential new revenue stream through future royalty payments
- R&D costs funded by partner company
- Expansion into growing psychedelic medicine market
- Validation of Polyrizon's intranasal delivery platform
- Agreement is non-binding with no guaranteed outcome
- No specific financial terms or royalty rates disclosed
- Timeline for proof of concept and definitive agreement not specified
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (“the psychedelic company”), to develop a novel intranasal formulation for psychedelic-based treatment applications.
This agreement aims to leverage Polyrizon’s proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy, and patient accessibility. If successful, this collaboration has the potential to pave the way for further clinical development and commercialization.
“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a prolonged drugs residence time and more efficient alternative to traditional administration methods,” said Tomer Izraeli CEO of Polyrizon.
According to the non-binding LOI, Polyrizon will lead the formulation’s development, utilizing its mucoadhesive drug delivery technology to enhance the absorption and effectiveness of the psychedelic company’s treatment. The psychedelic company will fund the research and development process, including feasibility studies, ensuring the project progresses efficiently toward clinical validation. Pursuing a successful outcome the two companies intend to negotiate a definitive agreement following proof of concept, outlining intellectual property ownership, commercialization rights, and financial terms. Polyrizon will receive royalty payments for any future commercialization of the product by the psychedelic company.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the execution of definitive agreements with the psychedelic company, its belief that intranasal delivery has the potential to improve patient outcomes by providing a prolonged drugs residence time and more efficient alternative to traditional administration methods and how this collaboration, if successful, has the potential to pave the way for further clinical development and commercialization. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC.. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
FAQ
What is the purpose of Polyrizon's (PLRZ) new partnership in psychedelic medicine?
How will the development costs be handled in Polyrizon's (PLRZ) psychedelic partnership?
What are the financial terms for Polyrizon (PLRZ) in this psychedelic medicine collaboration?
What is the current status of Polyrizon's (PLRZ) psychedelic medicine agreement?
